Changing global epidemiology of pulmonary manifestations of HIV/AIDS

Chest

Volumn 134, Issue 6, 2008, Pages 1287-1298

  Hull, Mark W ^a   Phillips, Peter ^a   Montaner, Julio S G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral therapy; HIV; Pulmonary disease; Resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; COTRIMOXAZOLE; EFAVIRENZ; FLUTICASONE PROPIONATE; ISONIAZID; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; RIFAMPICIN; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HEALTH CARE ORGANIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KAPOSI SARCOMA; MEDICAL CARE; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TUBERCULOSIS;

EID: 57349126820     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-0364     Document Type: Article

References (112)

1. Pneumocystis pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep Jun 5 1981; 30:250-252
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science May 20 1983; 220:868-871
3. Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220:865-867
4. UNAIDS/WHO. AIDS epidemic update. Available at: http://data.unaids.org/ pub/EPISlides/2007/2007_epiupdate_en.pdf. Accessed June 23, 2008
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733
6. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial: Italy, the Netherlands, Canada and Australia Study. JAMA 1998; 279:930-937
7. Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006; 130:1326-1333
8. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. Aids 2003; 17:371-375
9. Dye C, Scheele S, Dolin P, et al. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country; WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-686
10. Corbett EL, Steketee RW, ter Kuile FO, et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359:2177-2187
11. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2005. Atlanta, GA: US Department of Health and Human Services, 2005
12. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860
13. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454
14. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29
15. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Aids 2004; 18:887-895
16. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793
17. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40
18. Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immunocompromised HIV-infected patients in Cambodia. Aids 2007; 21:351-359
19. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38:174-179
20. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector; progress report 2008. Available at: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf. Accessed June 23 2008
21. Beck JM. The immunocompromised host: HIV infection. Proc Am Thorac Soc 2005; 2:423-427
22. Park IW, Koziel H, Hatch W, et al. CD4 receptor-dependent entry of human immunodeficiency virus type-1 envpseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor. Am J Respir Cell Mol Biol 1999; 20:864-871
23. Sierra-Madero JG, Toossi Z, Hom DL, et al. Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status. J Infect Dis 1994; 169:18-27
24. Murray HW, Gellene RA, Libby DM, et al. Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-γ. J Immunol 1985; 135:2374-2377
25. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998; 102:1332-1344
26. Ieong MH, Reardon CC, Levitz SM, et al. Human immunodeficiency virus type 1 infection of alveolar macrophages impairs their innate fungicidal activity. Am J Respir Crit Care Med 2000; 162:966-970
27. Bonecini-Almeida Mda G, Werneck-Barroso E, Carvalho PB, et al. Functional activity of alveolar and peripheral cells in patients with human acquired immunodeficiency syndrome and pulmonary tuberculosis. Cell Immunol 1998; 190:112-120
28. Semenzato G, Agostini C. HIV-related interstitial lung disease. Curr Opin Pulm Med 1995; 1:383-391
29. Das S, Miller RF. Lymphocytic interstitial pneumonitis in HIV infected adults. Sex Transm Infect 2003; 79:88-93
30. Guillon JM, Autran B, Denis M, et al. Human immunodeficiency virus-related lymphocytic alveolitis. Chest 1988; 94:1264-1270
31. Twigg HL, Soliman DM, Day RB, et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999; 159:1439-1444
32. Twigg HL III, Spain BA, Soliman DM, et al. Impaired IgG production in the lungs of HIV-infected individuals. Cell Immunol 1996; 170:127-133
33. Fahy RJ, Diaz PT, Hart J, et al. BAL and serum IgG levels in healthy asymptomatic HIV-infected patients. Chest 2001; 119:196-203
34. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus: Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-851
35. Mayaud C, Parrot A, Cadranel J. Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients. Eur Respir J Suppl 2002; 36:28s-39s
36. Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001; 184:268-277
37. Rimland D, Navin TR, Lennox JL, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. Aids 2002; 16:85-95
38. Scott JA, Hall AJ, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355:1225-1230
39. Feikin DR, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4:445-455
40. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43:90-98
41. Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-1258
42. Walson JL, Brown ER, Otieno PA, et al. Morbidity among HIV-1-infected mothers in Kenya: prevalence and correlates of illness during 2-year postpartum follow-up. J Acquir Immune Defic Syndr 2007; 46:208-215
43. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention; Franklin County Pneumonia Study Group. JAMA 1996; 275:194-198
44. Nuorti JP, Butler JC, Gelling L, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-190
45. Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347:718-723
46. Jones N, Huebner R, Khoosal M, et al. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. Aids 1998; 12:2177-2184
47. Sullivan JH, Moore RD, Keruly JC, et al. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med Jul 2000; 162:64-67
48. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial: Cotrimo-CI Study Group. Lancet 1999; 353:1463-1468
49. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469-1475
50. Dworkin MS, Ward JW, Hanson DL, et al. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800
51. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-2111
52. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-2045
53. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-1540
54. Le Moing V, Rabaud C, Journot V, et al. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med 2006; 7:261-267
55. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. Aids 2004; 18:1905-1913
56. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1: multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161-165
57. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(suppl 1):S5-S14
58. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection: EuroSIDA Study Group. Lancet 1999; 353:1293-1298
59. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy: eight European study groups. N Engl J Med 2001; 344:168-174
60. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection: Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344:159-167
61. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10:1713-1720
62. Soares EC, Saraceni V, Lauria Lde M, et al. Tuberculosis as a disease defining acquired immunodeficiency syndrome: ten years of surveillance in Rio de Janeiro, Brazil. J Bras Pneumol 2006; 32:444-448
63. Sritangratanakul S, Nuchprayoon S, Nuchprayoon I. Pneumocystis pneumonia: an update. J Med Assoc Thai 2004; 87(suppl 2):S309-S317
64. Nissapatorn V, Lee C, Fatt QK, et al. AIDS-related opportunistic infections in Hospital Kuala Lumpur. Jpn J Infect Dis 2003; 56:187-192
65. Chakaya JM, Bii C, Ng'ang'a L, et al. Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya. East Afr Med J 2003; 80:30-35
66. Worodria W, Okot-Nwang M, Yoo SD, et al. Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. Int J Tuberc Lung Dis 2003; 7:117-123
67. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182:551-557
68. Zar HJ, Alvarez-Martinez MJ, Harrison A, et al. Prevalence of dihydropteroate synthase mutants in HIV-infected South African children with Pneumocystis jiroveci pneumonia. Clin Infect Dis 2004; 39:1047-1051
69. Miller RF, Lindley AR, Ambrose HE, et al. Genotypes of Pneumocystis jiroveci isolates obtained in Harare, Zimbabwe, and London, United Kingdom. Antimicrob Agents Chemother 2003; 47:3979-3981
70. Worlh Health Organization. Global tuberculosis control 2008: surveillance, planning, financing. Available at: http://www.who.int/tb/ publications/global_report/2008/pdf/fullreport.pdf. Accessed June 23 2008
71. Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004; 10:388-398
72. Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926-937
73. El-Sadr WM, Perlman DC, Denning E, et al. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32:623-632
74. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Aids 2002; 16:75-83
75. Dheda K, Lampe FC, Johnson MA, et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670-1676
76. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. Aids 2007; 21:2521-2527
77. Kirk O, Gatell JM, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy: EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-872
78. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. Aids 2006; 20:1605-1612
79. Santoro-Lopes G, de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-546
80. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52(RR-11):1-77
81. Pozniak AL, Miller RF, Lipman MC, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005; (6 suppl 2):62-83
82. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-690
83. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61:389-393
84. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. Aids 2003; 17:637-638
85. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, et al. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther 2007; 12:515-521
86. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44:229-234
87. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194:479-485
88. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580
89. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196(suppl 1):S86-S107
90. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157:1881-1884
91. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium. Lancet 1999; 353:1843-1847
92. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153:317-324
93. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639-1646
94. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. Aids 2004; 18:1615-1627
95. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196(suppl 1):S63-S75
96. Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9
97. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373
98. Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43-49
99. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term followup. Clin Infect Dis 2005; 41:1483-1497
100. Niaura R, Shadel WG, Morrow K, et al. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis 2000; 31:808-812
101. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med Sep 2007; 28:575-587
102. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132:369-372
103. Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 1998; 53:459-467
104. Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394-4398
105. Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone [letter]. Aids 1999; 13:1803
106. Rouanet I, Peyriere H, Mauboussin JM, et al. Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone. HIV Med 2003; 4:149-150
107. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432
108. Grubb JR, Moorman AC, Baker RK, et al. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. Aids 2006; 20:1095-1107
109. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453
110. Cadranel J, Garfield D, Lavole A, et al. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 2006; 61:1000-1008
111. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110
112. Toward universal access: how WHO is working with countries to scale up HIV prevention. Geneva, Switzerland: World Health Organization, 2007